Jennifer R Cochran Selected Research

poly(diethylene glycol-l-lysine)-poly(l-lysine)

12/2010

Targeting of Cancer Cells Using Quantum Dot-Polypeptide Hybrid Assemblies that Function as Molecular Imaging Agents and Carrier Systems.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jennifer R Cochran Research Topics

Disease

50	Neoplasms (Cancer) 12/2022 - 07/2004
9	Glioblastoma (Glioblastoma Multiforme) 12/2021 - 03/2009
4	Brain Neoplasms (Brain Tumor) 12/2021 - 09/2013
4	Myocardial Infarction 01/2020 - 03/2015
4	Neoplasm Metastasis (Metastasis) 01/2018 - 01/2009
3	Infections 01/2022 - 12/2020
3	COVID-19 01/2021 - 08/2020
2	Pancreatic Neoplasms (Pancreatic Cancer) 12/2021 - 01/2016
2	Inflammation (Inflammations) 01/2017 - 07/2011
2	Chronic Pain 10/2016 - 10/2014
2	Medulloblastoma 01/2014 - 09/2013
2	Central Nervous System Neoplasms 01/2014 - 09/2013
1	Hematologic Neoplasms (Hematological Malignancy) 01/2022
1	Neuroblastoma 01/2022
1	Virus Diseases (Viral Diseases) 01/2021
1	Osteosarcoma (Osteogenic Sarcoma) 11/2020
1	Autoimmune Diseases (Autoimmune Disease) 01/2020
1	Cicatrix (Scar) 01/2020
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2020
1	Osteoporosis 01/2020
1	Myocardial Ischemia (Ischemic Heart Diseases) 01/2020
1	Ventricular Remodeling 01/2020
1	Atherosclerosis 01/2020
1	Adenocarcinoma of Lung 11/2019
1	Osteoarthritis 01/2018
1	Infarction (Infarctions) 10/2017
1	Ovarian Neoplasms (Ovarian Cancer) 01/2017
1	Pathologic Neovascularization 01/2017
1	Mesothelioma 01/2017
1	Corneal Neovascularization 01/2017
1	Malignant Mesothelioma 01/2017
1	Melanoma (Melanoma, Malignant) 12/2016

Drug/Important Bio-Agent (IBA)

26	IntegrinsIBA 01/2022 - 01/2009
22	Peptides (Polypeptides)IBA 01/2022 - 01/2009
16	Cystine-Knot MiniproteinsIBA 10/2016 - 03/2009
14	Proteins (Proteins, Gene)FDA Link 01/2020 - 09/2008
11	LigandsIBA 01/2022 - 11/2009
7	Cystine (L-Cystine)IBA 01/2016 - 02/2010
6	Pharmaceutical PreparationsIBA 12/2022 - 01/2016
6	CytokinesIBA 01/2022 - 12/2016
6	AntibodiesIBA 01/2021 - 03/2009
6	PeptidomimeticsIBA 01/2015 - 12/2009
5	HydrogelsIBA 01/2022 - 07/2009
3	Monoclonal AntibodiesIBA 01/2022 - 12/2016
3	Biocompatible Materials (Biomaterials)IBA 01/2022 - 02/2016
3	ErbB Receptors (EGF Receptor)IBA 12/2021 - 07/2004
3	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 01/2018 - 08/2011
3	Molecular Probes (Molecular Probe)IBA 01/2014 - 01/2013
3	Agouti-Related ProteinIBA 02/2013 - 02/2010
3	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 11/2010 - 03/2009
2	Immunoconjugates (Immunoconjugate)IBA 12/2021 - 01/2016
2	cardiotrophin-like cytokineIBA 01/2020 - 11/2019
2	matriptaseIBA 01/2018 - 01/2018
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2018 - 10/2017
2	Fluorescent Dyes (Fluorescent Probes)IBA 01/2014 - 09/2013
2	VitronectinIBA 02/2011 - 11/2009
2	Extracellular Matrix ProteinsIBA 02/2011 - 11/2009
2	AcidsIBA 11/2010 - 03/2009
2	CY5.5 cyanine dyeIBA 03/2010 - 03/2009
2	Trypsin InhibitorsIBA 03/2010 - 12/2009
2	Integrin beta3 (GPIIIa)IBA 02/2010 - 01/2009
1	Immunologic Adjuvants (Immunologic Adjuvant)IBA 01/2022
1	Lipid NanoparticlesIBA 01/2022
1	CalreticulinIBA 01/2022
1	Toll-Like Receptor 9IBA 01/2022
1	RNA (Ribonucleic Acid)IBA 01/2022
1	Leukemia Inhibitory FactorIBA 12/2021
1	depatuxizumab mafodotinIBA 12/2021
1	EpitopesIBA 01/2021
1	Viral RNAIBA 01/2021
1	Neutralizing AntibodiesIBA 01/2021
1	Membrane Glycoproteins (Membrane Glycoprotein)IBA 01/2021
1	Blood Proteins (Serum Proteins)IBA 01/2021
1	Immunoglobulin G (IgG)IBA 12/2020
1	Chimeric Antigen ReceptorsIBA 11/2020
1	Thymidine KinaseIBA 11/2020
1	9-(4-fluoro-3-hydroxymethylbutyl)guanineIBA 11/2020
1	GuanineIBA 11/2020
1	Ganciclovir (Cytovene)FDA LinkGeneric 11/2020
1	Angiotensin-Converting Enzyme 2IBA 08/2020
1	AutoantibodiesIBA 01/2020
1	Biological ProductsIBA 01/2020
1	LuciferasesIBA 01/2020
1	Nerve Growth Factor Receptors (Neurotrophin Receptors)IBA 11/2019
1	Immune Checkpoint ProteinsIBA 01/2019
1	Peptide Hydrolases (Proteases)FDA Link 01/2018
1	pro-hepatocyte growth factorIBA 01/2018
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2017
1	Serum AlbuminIBA 01/2017
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2017
1	Cell Surface ReceptorsIBA 12/2016
1	AntigensIBA 12/2016

Therapy/Procedure

13	Therapeutics 01/2021 - 09/2008
4	Immunotherapy 01/2022 - 12/2016
4	Injections 01/2022 - 02/2016
4	Drug Therapy (Chemotherapy) 01/2017 - 09/2013
2	Intravenous Administration 01/2022 - 01/2022
1	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2022
1	Ligation 01/2022
1	Catheters 01/2020